<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831723</url>
  </required_header>
  <id_info>
    <org_study_id>2107147</org_study_id>
    <nct_id>NCT04831723</nct_id>
  </id_info>
  <brief_title>NEWBIE Validate: Feasibility of a New Test to Measure Glucose in Newborn Blood Spots (NBS)</brief_title>
  <official_title>NEWBIE Validate: Feasibility of a New Test to Measure Glucose in Newborn Blood Spots (NBS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Devon and Exeter NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Health Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Portsmouth Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal Devon and Exeter NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this feasibility laboratory study is to evaluate whether the laboratory testing&#xD;
      pathway for glucose screening in newborn blood spots (NBS) can be done at scale, and that the&#xD;
      glucose test has a carefully established cut-off to define what level glucose is abnormal at&#xD;
      day 5 of life.&#xD;
&#xD;
      The investigators aim to run this feasibility study for a period of 6 to 12 months to fully&#xD;
      embed and test the process. This will equate to assessing glucose levels in approximately&#xD;
      10,000 NBS samples. The results from this study will inform a future large scale prospective&#xD;
      screening study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Normal range of capillary blood glucose in newborns at day 5 of life</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validation of laboratory procedures</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Neonatal Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Babies having a routine NBS screening test within the areas served by the Portsmouth&#xD;
        regional screening laboratory (NHS Trusts within Hampshire, Dorset &amp; parts of Wiltshire)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Babies having a routine NBS screening test.&#xD;
&#xD;
          -  Routine maternity care team within the area served by the Portsmouth regional&#xD;
             screening laboratory (NHS Trusts within Hampshire, Dorset &amp; parts of Wiltshire)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Parent decides to opt-out of the blood glucose test feasibility study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Mcdonald</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Devon and Exeter NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucy Gates</last_name>
    <phone>01392 408181</phone>
    <email>lucy.gates1@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anita Hill</last_name>
    <email>anita.hill2@nhs.net</email>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 1, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

